Trametinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Trametinib and local guidelines before prescribing.
MEK inhibitor
Mechanism
MEK inhibitor.
Uses
BRAF V600 melanoma and other cancers (with dabrafenib).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Rash, diarrhoea, cardiomyopathy, pyrexia, eye toxicity.
Interactions
Few.
Contraindications and cautions
Pregnancy
Monitoring
LVEF, eyes
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in hepatic impairment
Overdose and reversal
Supportive
Special advice
Combination fever pathway.
More from the textbook: uses, cautions and other points
- Adjuvant treatment (stage IIB–III, after surgery) - immunotherapy (pembrolizumab or nivolumab) for 1 year, or BRAF/MEK inhibitors (dabrafenib with trametinib) if BRAF-mutated. Neoadjuvant immunotherapy for some resectable stage III disease.
Oncology: Skin Cancer - Dabrafenib + trametinib | BRAF-mutated melanoma; fever, rash.
Oncology: Skin Cancer - Adjuvant treatment (after surgery for high-risk stage IIB–III) - immunotherapy (pembrolizumab, nivolumab) or BRAF/MEK inhibitors (dabrafenib with trametinib) for BRAF-mutant stage III.
Dermatology: Skin lesions and skin cancer - Dabrafenib + trametinib | BRAF V600-mutant melanoma - fever (pyrexia syndrome).
Dermatology: Skin lesions and skin cancer - BRAF/MEK | Dabrafenib + trametinib | BRAF V600E melanoma
Cell Biology: Cell cycle, signalling, cell death and stem cells
Where it is discussed in the book
- Oncology: Skin Cancer (2 mentions)
- Dermatology: Skin lesions and skin cancer (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)